Am­gen joins a mar­quee list of part­ners jump­ing on Nuevo­lu­tion’s dis­cov­ery plat­form

You can add Am­gen to the list of big bio­phar­ma com­pa­nies that have part­nered with Copen­hagen-based Nuevo­lu­tion and its small mol­e­cule dis­cov­ery plat­form.

Nuevo­lu­tion will put its plat­form — dubbed Chemet­ics — to work find­ing new can­cer and neu­ro­science drugs for Am­gen. Am­gen gets an op­tion on all world­wide rights to any­thing it wants for it­self, and Nuevo­lu­tion can earn up to $410 mil­lion in the full slate of mile­stones for any ther­a­py that goes the dis­tance.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER